Status:
COMPLETED
A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma
Lead Sponsor:
ProgenaBiome
Conditions:
Mesothelioma
Eligibility:
All Genders
Phase:
EARLY_PHASE1
Brief Summary
The investigators propose to ensure a favorable gut microbiome by fecal microbiota transplant to enhance the efficacy Keytruda
Detailed Description
Studies have shown that a favorable microbiome can be the difference between response and non-response of certain cancer treatments such as PD-1 blockade inhibitors. As such the investigators propose ...
Eligibility Criteria
Inclusion
- Patient with metastatic mesothelioma deemed a candidate for PD-1 blockade inhibitor therapy
Exclusion
- Patient unable/unwilling to comply with protocol
- Patient deemed not a candidate for PD-1 Blockade inhibitor therapy
Key Trial Info
Start Date :
September 18 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2018
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04056026
Start Date
September 18 2018
End Date
December 18 2018
Last Update
September 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ProgenaBiome
Ventura, California, United States, 93003